SCHEMBL4441997

SCHEMBL4441997

CC(CO)OC(=O)O[C@]1(C(=O)O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3CC[C@@]21C

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.55
MAPT P10636 2/20 0.55
CYP19A1 P11511 9/20 0.47
NR3C1 P04150 3/20 0.47
PGR P06401 3/20 0.47
CYP3A4 P08684 2/20 0.47
ABCC3 O15438 1/20 0.47
NR1I2 O75469 1/20 0.47
ABCB11 O95342 1/20 0.47
HIF1A Q16665 2/20 0.46
USP2 O75604 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
HSD17B10 Q99714 3/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
KMT2A Q03164 1/20 0.45
SLC29A1 Q99808 1/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6439469 0.87 LMNA (0.59) LMNAMAPTCYP19A1NR3C1PGR
SCHEMBL4455690 0.86 LMNA (0.55) LMNAMAPTCYP19A1NR3C1PGR
SCHEMBL4807382 0.84 LMNA (0.59) LMNAMAPTCYP19A1NR3C1PGR
SCHEMBL4444218 0.83 AR (0.61) LMNAMAPTNR3C1PGRCYP3A4
SCHEMBL5195019 0.82 LMNA (0.59) LMNAMAPTCYP19A1NR3C1PGR
SCHEMBL3679824 0.78 NR3C1 (0.64) LMNANR3C1PGRCYP3A4ABCC3
SCHEMBL6447018 0.77 LMNA (0.65) LMNAMAPTCYP19A1NR3C1PGR
SCHEMBL6449571 0.77 LMNA (0.65) LMNAMAPTCYP19A1NR3C1PGR
SCHEMBL11817969 0.77 LMNA (0.62) LMNAMAPTCYP19A1PGRCYP3A4
SCHEMBL4210068 0.76 LMNA (0.59) LMNAMAPTCYP19A1NR3C1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2026818-A2 COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY Bodor, Nicholas S. (US) 2009-02-25 EP claimed
WO-2007142842-A2 COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY BODOR NICHOLAS S (US) 2007-12-13 WO claimed
EP-2026818-A2 COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY Bodor, Nicholas S. (US) 2009-02-25 EP disclosed
WO-2007142842-A2 COMBINATION OF ANTI-INFLAMMATORY STEROIDS HAVING TRANSPORTER-ENHANCED CORTICOSTEROID ACTIVITY BODOR NICHOLAS S (US) 2007-12-13 WO disclosed
EP-1653974-A1 ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION BODOR, Nicholas S. (US) 2006-05-10 EP disclosed
US-20050026892-A1 Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application BODOR LABORATORIES, INC. 2005-02-03 US disclosed
WO-2005000317-A1 ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION BODOR NICHOLAS S (US) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026892-A1 Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application OXER1, ELOVL6, ELOVL3 LMNA 1749/4885MAPT 4856/4885CYP19A1 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.